دورية أكاديمية
أعرض في EDS

Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation.

التفاصيل البيبلوغرافية
العنوان: Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation.
المؤلفون: Muderrisoglu A; Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Babaoglu E; Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Korkmaz ET; Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Ongun MC; Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Karabulut E; Department of Biostatistics, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Iskit AB; Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Emri S; Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Babaoglu MO; Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
المصدر: Frontiers in genetics [Front Genet] 2020 Nov 30; Vol. 11, pp. 571997. Date of Electronic Publication: 2020 Nov 30 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101560621 Publication Model: eCollection Cited Medium: Print ISSN: 1664-8021 (Print) Linking ISSN: 16648021 NLM ISO Abbreviation: Front Genet Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Research Foundation.
مستخلص: Objectives: To determine the effects of genetic polymorphisms of ABCB1 (MDR1), CYP2A6, CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a Turkish population.
Methods: 130 smokers and 130 non-smokers were recruited. Individuals who never smoked were described as non-smokers. 130 smokers were treated with nicotine replacement therapy (NRT) ( n = 40), bupropion ( n = 47), bupropion + NRT ( n = 15), and varenicline ( n = 28). Smokers were checked by phone after 12 weeks of treatment whether they were able to quit smoking or not. Genotyping and phenotyping were performed.
Results: Cessation rates were as follows; 20.0% for NRT, 29.8% for bupropion, 40.0% for bupropion + NRT, 57.1% for varenicline ( p = 0.013). The frequency of ABCB1 1236TT-2677TT-3435TT haplotype was significantly higher in non-smokers as compared to smokers (21.5% vs. 10.8, respectively; p = 0.018). Neither smoking status nor smoking cessation rates were associated with genetic variants of CYP2A6 ( p = 0.652, p = 0.328, respectively), or variants of CYP2B6 ( p = 0.514, p = 0.779, respectively).
Conclusion: Genetic variants of the drug transporter ABCB1 and the 1236TT-2677TT-3435TT haplotype was significantly associated with non-smoking status. Neither ABCB1 nor CYP2A6, CYP2B6 genetic variants were associated with smoking cessation rates at the 12th week of drug treatment.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2020 Muderrisoglu, Babaoglu, Korkmaz, Ongun, Karabulut, Iskit, Emri and Babaoglu.)
References: Neuron. 2011 Apr 14;70(1):20-33. (PMID: 21482353)
Clin Pharmacol Ther. 2001 Aug;70(2):189-99. (PMID: 11503014)
J Am Soc Nephrol. 2002 Jul;13(7):1847-54. (PMID: 12089380)
Drug Des Devel Ther. 2018 Jul 10;12:2139-2147. (PMID: 30022812)
Neuropsychopharmacology. 2015 Jul;40(8):1910-8. (PMID: 25652250)
Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1337-54. (PMID: 25162314)
Clin Pharmacol Ther. 2006 Nov;80(5):457-67. (PMID: 17112802)
Eur J Clin Pharmacol. 2015 Sep;71(9):1067-73. (PMID: 26153084)
Xenobiotica. 2010 Jun;40(6):381-92. (PMID: 20307138)
Trends Pharmacol Sci. 2017 Jan;38(1):55-66. (PMID: 27712845)
Clin Pharmacol Ther. 2012 Dec;92(6):771-7. (PMID: 23149928)
J Natl Cancer Inst. 2002 Jan 16;94(2):108-15. (PMID: 11792749)
Biol Psychiatry. 2007 Sep 15;62(6):635-41. (PMID: 17223085)
Carcinogenesis. 2016 Mar;37(3):269-279. (PMID: 26818358)
Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):354-60. (PMID: 25286968)
Pharmacogenet Genomics. 2011 Mar;21(3):152-61. (PMID: 20216335)
Xenobiotica. 2008 Jul;38(7-8):802-32. (PMID: 18668431)
Pharmacol Biochem Behav. 2009 Mar;92(1):6-11. (PMID: 19000709)
Sci Rep. 2020 Jul 27;10(1):12457. (PMID: 32719417)
Life Sci. 2011 May 23;88(21-22):959-71. (PMID: 20932495)
Head Neck. 2015 Dec;37(12):1712-21. (PMID: 24986226)
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8. (PMID: 10716719)
Basic Clin Pharmacol Toxicol. 2017 Feb;120(2):199-206. (PMID: 27611887)
Clin Pharmacol Ther. 2001 Mar;69(3):169-74. (PMID: 11240981)
Addict Biol. 2005 Jun;10(2):127-9. (PMID: 16191663)
Drug Metab Pharmacokinet. 2016 Dec;31(6):417-424. (PMID: 27836711)
Pharmacogenet Genomics. 2013 Feb;23(2):94-103. (PMID: 23249876)
Br J Clin Pharmacol. 2002 Dec;54(6):610-6. (PMID: 12492608)
Cancer Cell Int. 2005 Oct 04;5:30. (PMID: 16202168)
Pharmacogenet Genomics. 2009 May;19(5):388-98. (PMID: 19300303)
Peptides. 2001 Dec;22(12):2015-20. (PMID: 11786185)
Clin Pharmacol Ther. 2006 Sep;80(3):282-97. (PMID: 16952495)
Hum Mol Genet. 2008 Jul 15;17(14):2219-27. (PMID: 18424454)
Lancet Respir Med. 2015 Feb;3(2):131-138. (PMID: 25588294)
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1812-9. (PMID: 17035386)
Pharmacogenet Genomics. 2005 Oct;15(10):693-704. (PMID: 16141795)
Clin Pharmacokinet. 2015 Jul;54(7):709-35. (PMID: 25860377)
J Pers Med. 2017 Dec 01;7(4):. (PMID: 29194389)
Toxicol Lett. 2009 Mar 10;185(2):116-23. (PMID: 19135510)
Pharmacogenet Genomics. 2010 Aug;20(8):520-3. (PMID: 20648701)
Clin Pharmacol Ther. 2008 Apr;83(4):531-41. (PMID: 18305452)
Mol Biol Rep. 2014 Jun;41(6):3891-6. (PMID: 24562623)
Ann N Y Acad Sci. 2010 Feb;1187:184-207. (PMID: 20201854)
Clin Pharmacol Ther. 2006 Jun;79(6):600-8. (PMID: 16765148)
PLoS Genet. 2015 Sep 25;11(9):e1005498. (PMID: 26407342)
Cochrane Database Syst Rev. 2012 Nov 14;11:CD000146. (PMID: 23152200)
J Rheumatol. 2007 Jul;34(7):1540-4. (PMID: 17610314)
فهرسة مساهمة: Keywords: P-glycoprotein; addiction; cytochrome P450 enzymes; genetic polymorphism; nicotine
تواريخ الأحداث: Date Created: 20201217 Latest Revision: 20220419
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7734344
DOI: 10.3389/fgene.2020.571997
PMID: 33329709
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-8021
DOI:10.3389/fgene.2020.571997